The Youth Opioid Recovery Support (YORS) Intervention

Summary

Youth are disproportionately affected by the current opioid crisis with catastrophic consequences, and young adults with opioid use disorder (OUD) often struggle with adherence to relapse prevention medications. The Youth Opioid Recovery Support (YORS) model is a promising, innovative, wrap-around approach that addresses barriers to medication adherence and treatment engagement in an effort to improve public health outcomes in this vulnerable young adult population. This study seeks to refine the YORS intervention through stakeholder input and pilot iterative testing followed by an efficacy randomized controlled trial. This project will significantly contribute to our knowledge base of practical strategies to address the opioid crisis.

Conditions

• Opioid-use Disorder
• Medication Adherence

Interventions

BEHAVIORAL

Youth Opioid Recovery Support (YORS)

The Youth Opioid Recovery Support (YORS) model is an innovative wrap-around approach that attempts to address barriers to treatment engagement in this vulnerable young adult population, especially difficulties with medication adherence. Its components include: (1) Home delivery of extended release naltrexone (XR-NTX) for OUD; (2) Engagement of families in collaborative treatment planning and monitoring focusing on medication adherence; (3) Assertive outreach from the treatment team including actively tracking and communicating with youth and families by text messaging and social media to promote engagement and adherence; and (4) Contingency management to provide incentives for medication adherence.

Sponsors & Collaborators

• National Institutes of Health (NIH)

  collaborator NIH

• Friends Research Institute, Inc.

  collaborator OTHER

• National Center for Complementary and Integrative Health (NCCIH)

  collaborator NIH

• National Institute on Drug Abuse (NIDA)

  collaborator NIH

• Potomac Health Foundations

  lead OTHER

Principal Investigators

• Marc Fishman, MD · Maryland Treatment Centers

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

28 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-02-17

Primary Completion

2026-08-31

Completion

2026-08-31

Countries

• United States

Study Locations